| Stereochemistry | ACHIRAL |
| Molecular Formula | C9H10N2O |
| Molecular Weight | 162.1885 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1CCN(N1)C2=CC=CC=C2
InChI
InChIKey=CMCWWLVWPDLCRM-UHFFFAOYSA-N
InChI=1S/C9H10N2O/c12-9-6-7-11(10-9)8-4-2-1-3-5-8/h1-5H,6-7H2,(H,10,12)
| Molecular Formula | C9H10N2O |
| Molecular Weight | 162.1885 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
1-Phenyl-3-pyrazolidinone (phenidone) is a dual inhibitor of cyclooxygenase (COX) and lipoxygenase (LOX). Phenidone inhibits both the LO (lipoxygenase) and Cox (cyclooxygenase) pathways, the synthesis of Fos-related antigen protein, and is described as an anti-inflammatory and anti-oxidant compound. Phenidone is a potent hypotensive agent in the spontaneously hypertensive rat. Phenidone was also the best in suppressing LPS induced
neurotoxicity, where the more potent neuroprotection by
phenidone may be attributable to the synergistic effects of dual COX
and LOX inhibition. Therefore, dual inhibitors of COX and LOX, such
as phenidone, represent valuable candidates for the development of
novel drugs for inflammation-related neurodegenerative disorders
including PD.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Rats: phenidone (25, 50 or 100 mg/kg) was administered orally five times every 12 h before the injection of KA (10 mg/kg, i.p.).
Route of Administration:
Oral